[go: up one dir, main page]

WO2008014299A3 - Méthodes et compositions utiles pour le traitement de l'hyperlipidémie - Google Patents

Méthodes et compositions utiles pour le traitement de l'hyperlipidémie Download PDF

Info

Publication number
WO2008014299A3
WO2008014299A3 PCT/US2007/074284 US2007074284W WO2008014299A3 WO 2008014299 A3 WO2008014299 A3 WO 2008014299A3 US 2007074284 W US2007074284 W US 2007074284W WO 2008014299 A3 WO2008014299 A3 WO 2008014299A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperlipidemia
alpha2
treatment
agonist composition
adrenergic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/074284
Other languages
English (en)
Other versions
WO2008014299A2 (fr
Inventor
Jyotirmoy X Kusari
Daniel W Gil
John E Donello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of WO2008014299A2 publication Critical patent/WO2008014299A2/fr
Publication of WO2008014299A3 publication Critical patent/WO2008014299A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement de l'hyperglycémie ou de l'hyperlipidémie dans laquelle on utilise un agoniste des sous-types du récepteur adrénergique α2B et/ou α2C qui manquent (a) d'une activité significative du récepteur adrénergique α2A et/ou (b) d'une activité significative du récepteur adrénergique α1A.
PCT/US2007/074284 2006-07-27 2007-07-25 Méthodes et compositions utiles pour le traitement de l'hyperlipidémie Ceased WO2008014299A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82052606P 2006-07-27 2006-07-27
US60/820,526 2006-07-27

Publications (2)

Publication Number Publication Date
WO2008014299A2 WO2008014299A2 (fr) 2008-01-31
WO2008014299A3 true WO2008014299A3 (fr) 2008-04-24

Family

ID=38825013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/074284 Ceased WO2008014299A2 (fr) 2006-07-27 2007-07-25 Méthodes et compositions utiles pour le traitement de l'hyperlipidémie

Country Status (1)

Country Link
WO (1) WO2008014299A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046239A1 (fr) * 1996-06-06 1997-12-11 Ergo Research Corporation Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine
US20020161051A1 (en) * 2001-02-27 2002-10-31 Allergan Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
WO2003030903A1 (fr) * 2001-10-05 2003-04-17 Arachnova Therapeutics Ltd. Utilisation de la tizanidine pour traiter des troubles metaboliques associes a une secretion anormale d'insuline
US20050075366A1 (en) * 2002-05-21 2005-04-07 Heidelbaugh Todd M. 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same
WO2005034849A2 (fr) * 2003-09-12 2005-04-21 Allergan, Inc. Nouvelles methodes d'identification d'agonistes $g(a)-2 non sedatifs ameliores
WO2007090733A1 (fr) * 2006-02-06 2007-08-16 Nicox S.A. Dérivés nitrooxy utilisables comme agonistes des récepteurs alpha 2 adrénergiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046239A1 (fr) * 1996-06-06 1997-12-11 Ergo Research Corporation Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine
US20020161051A1 (en) * 2001-02-27 2002-10-31 Allergan Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
WO2003030903A1 (fr) * 2001-10-05 2003-04-17 Arachnova Therapeutics Ltd. Utilisation de la tizanidine pour traiter des troubles metaboliques associes a une secretion anormale d'insuline
US20050075366A1 (en) * 2002-05-21 2005-04-07 Heidelbaugh Todd M. 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same
WO2005034849A2 (fr) * 2003-09-12 2005-04-21 Allergan, Inc. Nouvelles methodes d'identification d'agonistes $g(a)-2 non sedatifs ameliores
WO2007090733A1 (fr) * 2006-02-06 2007-08-16 Nicox S.A. Dérivés nitrooxy utilisables comme agonistes des récepteurs alpha 2 adrénergiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALAZOVJECH I ET AL: "The effect of small doses of guanfacine (Estulic Sandoz) on the lipid levels and catecholamine excretion in patients with essential hypertension.", COR ET VASA, VOL. 29, NO. 4 SUPPL 1, PP. 46-52. JOURNAL CODE: 0372614. ISSN: 0010-8650., 1987, XP008088535 *
REITER J ET AL: "SYNTHESIS OF NEW BENZYL THIO UREA DERIVATIVES AND THEIR CYCLIC ANALOGS WITH DIURETIC AND SALURETIC ACTIVITY", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 1, 1980, pages 41 - 53, XP001109342, ISSN: 0223-5234 *
SATIA MILAN C ET AL: "Beneficial effects of clonidine in streptozotocin-induced diabetes and DOCA-hypertensive rats", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 49, no. 10, October 1997 (1997-10-01), pages 1030 - 1035, XP008088536, ISSN: 0022-3573 *
VELLIQUETTE RODNEY A ET AL: "Contrasting metabolic effects of antihypertensive agents.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 307, no. 3, December 2003 (2003-12-01), pages 1104 - 1111, XP002470476, ISSN: 0022-3565 *
VELLIQUETTE RODNEY A ET AL: "Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, (2006 JAN) VOL. 372, NO. 4, PP. 300-12. ELECTRONIC PUBLICATION: 2006-01-17. JOURNAL CODE: 0326264. ISSN: 0028-1298., 17 January 2006 (2006-01-17), XP019326113 *

Also Published As

Publication number Publication date
WO2008014299A2 (fr) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2007111864A3 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d&#39;utilisation
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d&#39;utilisation
WO2009129433A3 (fr) Agonistes des récepteurs alpha-adrénergiques destinés au traitement de la discopathie dégénérative
WO2007133518A3 (fr) Agents modulateurs pour revêtements antimicrobiens
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
WO2008087491A8 (fr) Procédé de traitement ou de prévention de symptômes de variations hormonales
WO2005102338A8 (fr) Methode de traitement de la douleur neuropathique au moyen d&#39;un antagoniste du recepteur crth2
WO2008100457A3 (fr) Agonistes fonctionnellement sélectifs du récepteur adrénergique alpha2c
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
WO2007003962A3 (fr) Agonistes de gpcr
WO2007003961A3 (fr) Agonistes de gpcr
PT2142519E (pt) Inibidor de dpp-iv incluindo grupo beta-amino, o seu método de preparação e composição farmacêutica contendo o mesmo, para prevenção e tratamento de diabetes ou obesidade
TWI348342B (en) Method of setting reference value for examining substrate, and device and program using the same
PT1986642E (pt) Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
CL2007002888A1 (es) Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular.
WO2010033495A3 (fr) Agonistes de l&#39;adrénorécepteur α2c à base d&#39;azanitrile fonctionnellement sélectifs
WO2008100456A3 (fr) Agonistes des récepteurs adrénergiques alpha2c fonctionnellement sélectifs
UA96573C2 (ru) Антагонисты кинина для лечения дисфункции мочевого пузыря
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2008079727A3 (fr) Compositions contenant un agoniste du récepteur adrénergique pan-alpha-2 et un anticonvulsif, destinées à traiter la douleur chronique
EP2055695A4 (fr) Formule pour alkylation et méthode de détoxication d&#39;un composé toxique à l&#39;aide de ladite formule
WO2008014299A3 (fr) Méthodes et compositions utiles pour le traitement de l&#39;hyperlipidémie
WO2007118073A3 (fr) Obésité et distribution de graisse corporelle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813322

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07813322

Country of ref document: EP

Kind code of ref document: A2